Pacira BioSciences - PCRX Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings or view top-rated stocks.

8 brokerages have issued twelve-month target prices for Pacira BioSciences' stock. Their PCRX share price forecasts range from $60.00 to $96.00. On average, they anticipate the company's stock price to reach $77.33 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for PCRX or view top-rated stocks among Wall Street analysts.

Pacira BioSciences' stock was trading at $60.17 on January 1st, 2022. Since then, PCRX stock has decreased by 20.7% and is now trading at $47.69.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PCRX earnings forecast.

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, November, 3rd. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.02. The business earned $167.47 million during the quarter, compared to analysts' expectations of $167.30 million. Pacira BioSciences had a net margin of 3.19% and a trailing twelve-month return on equity of 12.34%.

Pacira BioSciences issued an update on its third quarter 2022 earnings guidance on Thursday, October, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $167.50 million-$167.50 million, compared to the consensus revenue estimate of $172.72 million.

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.61%), Macquarie Group Ltd. (6.39%), Baillie Gifford & Co. (4.07%), Renaissance Technologies LLC (3.82%), Armistice Capital LLC (3.47%) and Spyglass Capital Management LLC (2.73%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Dennis Mcloughlin, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends.

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PCRX stock can currently be purchased for approximately $47.69.

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $2.19 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.41 on an earnings per share basis.

The company employs 697 workers across the globe.

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.